Clinical trial
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With…
NCT00083889 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00083889 |
|---|---|
| Title | SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma |
| Official title | A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Interferon-alfa, SU011248 |
| Enrollment | 750 |
| Start date | Aug 1, 2004 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Jun 4, 2004 |
| Last update posted | Jan 26, 2010 |
| Countries | Australia, Brazil, Canada, France, Germany, Italy, Poland, Russia, Spain, United Kingdom, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: